Corona Cero Unveils Global Roster of Athlete Ambassadors to Champion TIME CERO at Milano Cortina 2026
3.2.2026 09:00:00 CET | Business Wire | Press Release
Corona Cero today unveiled its global roster of brand ambassadors who will champion TIME CERO, the brand’s new initiative created in partnership with the IOC and Athlete365, throughout the Olympic Winter Games. Together, Team Corona Cero will bring the brand’s “For Every Golden Moment” global platform to life, reminding people that meaningful golden moments can happen anytime, anywhere, or in any season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203205858/en/
Team Corona Cero
Central to Corona Cero’s commitment as a Worldwide Olympic Partner, TIME CERO is designed to celebrate Olympians and help them relax, stay present, and embrace balance amid the intensity of competition. Activated across a range of Olympic Games locations, all Winter Olympians at Milano Cortina 2026 will be able to embrace TIME CERO through nature-inspired spaces and post-competition retreats.
“'For Every Golden Moment’ is more than medals or milestones — it’s also about the small, meaningful moments that make the Olympic journey unforgettable,” said Richard Oppy, AB InBev Global President, Premium Brands. “Our Corona Cero ambassadors and other Olympians will get the chance to enjoy TIME CERO, a moment to unwind, relax, and truly take it all in — whether that is on the slopes, in the village, or even back home celebrating with friends and a beer in hand.”
Meet Team Corona Cero
Representing the brand across Milano Cortina 2026, the global roster of Corona Cero ambassadors includes:
- Arianna Fontana (Italy, Short Track Speed Skating)
- Ayumu Hirano (Japan, Snowboard)
- Cassie Sharpe (Canada, Freestyle Skiing)
- Katie Ormerod (Great Britain, Snowboard)
- Lucas Pinheiro Braathen (Brazil, Alpine Skiing)
- Marie-Philip Poulin (Canada, Ice Hockey)
- Mark McMorris (Canada, Snowboard)
- Matt C. Smith (South Africa, Cross-Country Skiing)
- Matt Weston (Great Britain, Skeleton)
- Suzanne Schulting (Netherlands, Speed Skating)
These athletes will live the “For Every Golden Moment” platform in real time by sharing personal Olympic Games journeys, balancing peak performance and mindful reflection with TIME CERO, and connecting with fans at special events.
Introducing TIME CERO: Relax, Recharge, and Celebrate
Corona Cero’s TIME CERO initiative begins for all Team Corona Cero ambassadors with the signing of the brand’s Relaxation Clause: a commitment that ensures all partners prioritize downtime, recovery, and presence throughout the Olympic Games. The Relaxation Clause offers a new approach to partnerships that reflects the essence of Corona Cero: giving athletes flexibility to embrace balance and connect with nature.
Since the Olympic Games Paris 2024, Corona Cero has developed one-of-a-kind spaces for athletes to connect with nature, and the brand is now taking it to a new level. In Milano Cortina 2026, Corona Cero has created “Cero Stress Zones” across the Olympic Villages for all athletes to use — dedicated spaces filled with nature to help them recharge between competitions — complete with “Mobile Plant Shops” to bring plants back to their personal rooms for an added touch of nature.
To honor and celebrate the monumental occasion, athletes will receive Corona Cero’s legendary Golden Bottle — an engravable keepsake commemorating their own Olympic Winter Games golden moments. The brand has also created multiple Casa Corona hospitality zones for athletes from all nations to come together for celebrations, as well as being included within select country-themed National Olympic Committee (NOC) houses.
After the Olympic Winter Games, Team Corona Cero ambassadors will have the chance to participate in a TIME CERO Retreat on Corona Island — the brand’s eco-protected paradise off Colombia’s coast — where they can celebrate their achievements and reconnect with nature in a Michelin-rated experience.
“The Winter Olympic Games move fast, and it is easy to miss how special each moment really is,” said Cassie Sharpe, Canadian freestyle skier and Corona Cero athlete ambassador. “What drew me to Team Corona Cerois the idea that success is not only about results, but about how you experience the journey. TIME CERO reflects something I truly believe in: slowing down, staying present, and appreciating that the moments that happen along the way are just as important as the competition itself.”
Creating Lasting Moments Throughout Milano Cortina 2026
Fans of a legal drinking age will have opportunities to engage with Corona Cero in Milano and Livigno, immersing themselves in the spirit of the Olympic Games and Corona Cero’s celebration of connection, balance, and mindful enjoyment.
Through these brand activations — including the Corona Hotel mountain lodge, Casa Corona hospitality centers, beer gardens, and other special pop-ups — spectators can escape the bustle to relax, reflect, and celebrate their own golden moments. Produced by experiential partner, WINK, many of Corona Cero’s activations are Blue Standard verified by Oceanic Global, ensuring structures are built with sustainability in mind, reduce single-use plastics, and follow best-practices for sourcing waste systems.
The “For Every Golden Moment” platform, created in partnership with the creative agency Grey, draws parallels with real-life events and Olympic triumphs to show that golden moments can be experienced anywhere in the world.
To learn more, follow @Corona on social media for access details, exclusive updates, and real-time coverage of all Milano Cortina 2026 activations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260203205858/en/
Contacts
media.relations@ab-inbev.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom